1	The Destavial Dusfile and	Antibiotic Cuccontibil	ity Dattawa in Da	aninatany Traat Ca	una na la a fua na
	The bacterial Profile and	Antibiolic Susceptibil	itv Pattern in Ke	SDIFALORY I FACE Sa	ampies from
-					

- 2 ART-Experienced HIV-Positive Adults in Uganda.
- 3
- 4 Authors
- 5 Lubega Gloria<sup>1\*</sup>, Abaasa Andrew<sup>1,4</sup>, Willyfred Ochola<sup>1</sup>, Bernard Kikaire<sup>2,3</sup>, Joseph Lutaakome<sup>1</sup>,
- 6 Eugene Rugazira<sup>1,4</sup>, Yunia Mayanja<sup>1,4</sup>
- 7 1. Medical Research Council /Uganda Virus Research Institute and London School of
- 8 Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
- 9 2. Uganda Virus Research Institute, Entebbe, Uganda
- 10 3. Department of paediatrics, College of Health Sciences, Makerere University, Kampala,
- 11 Uganda
- 12 4. London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT
- 13

### 14 **\*Corresponding author:**

- 15 Email: Gloria.Lubega@mrcuganda.org (LG)
- 16
- . -
- 17
- 18
- 19
- 17

- 21
- 22

# 23 Abstract

Introduction: Microbial infections are a major cause of morbidity and mortality among people
living with HIV (PLWH). Respiratory tract infections (RTIs) are responsible for approximately 70%
of illnesses among PLWH. Drug resistant bacteria are highly prevalent among PLWH and this is a
public health concern.

Methods: This is a retrospective analysis of data collected during the COSTOP trial between 2011 and 2013. Sputum collected on spot from participants presenting with a productive cough was examined using Gram, Ziehl-Neelsen stains and cultured on suitable bacteriological media. Antimicrobial sensitivity testing was done on isolated pathogens, by disc diffusion technique.

32 **Results:** We included 687 participants with mean age 41.3 (SD 8.2) years of whom 76.4% were 33 female. Two hundred one sputum samples grew bacteria; Moraxella species (27.4%), 34 Streptococcus pneumoniae(25.4%), Haemophilus *influenza*(22.4%), Mycobacterium 35 species(4.5%), Pseudomonas species(4.0%), Staphylococcus aureus(4.0%), Escherichia coli (1.0%), 36 Klebsiella species (1.0%), other bacteria (10.4%). A higher monthly income greater than or equal 37 to 30\$ (aOR= 0.63, 95%CI: 0.40-0.99) and longer duration since HIV diagnosis (aOR= 1.06, 95%CI: 38 1.0-1.11) were found to be independently associated with a positive bacterial culture. Moraxella 39 sp, H. influenza and Pseudomonas had zero sensitivity towards cotrimoxazole. Sensitivity to 40 erythromycin was low among Moraxella sp (28.6%), H. influenza (31.6%) and S. aureus(42.9%) 41 and other bacteria (42.9%). Most isolates were sensitive to Amoxicillin + Clavulanic acid and 42 ceftriaxone.

- 43 **Conclusion:** There is a very low sensitivity of isolated bacteria to commonly prescribed antibiotics
- 44 that are more available through the national supply chain, which is of public health concern.
- 45 Urgent steps to tackle the high antimicrobial resistance among PLWH is required.

46

- 47 **Keywords:** PLWH, Bacteria, Antimicrobial Susceptibility, Antibiotic, Respiratory tract Infection
- 48
- 49 Abbreviations
- 50 API Analytical profile index
- 51 AMR Antimicrobial Resistance
- 52 ART Antiretroviral therapy
- 53 CD4 Cluster of Differentiation 4
- 54 COSTOP Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults in
- 55 Uganda: a randomised controlled trial
- 56 EUCAST European Committee on Antimicrobial Susceptibility Testing
- 57 HIV Human Immune Deficiency Virus
- 58 PLWH People living with HIV
- 59 RTIs Respiratory tract infections
- 60 SSA Sub-Saharan Africa

61

# 64 Introduction

65 For over three decades, Human Immunodeficiency Virus (HIV) infection remains a disease of 66 public health importance with approximately 37.6 million people living with HIV (PLWH) globally 67 in 2020 (1). Sub-Saharan Africa (SSA) suffers the highest burden of HIV with nearly 70% of global 68 HIV infections (2). Since the introduction of antiretroviral therapy (ART), PLWH have an improved 69 guality of life however, microbial infections are still a major cause of morbidity and mortality 70 among this population (3), with approximately 70% of illnesses being respiratory tract infections 71 (RTIs) (4, 5). Ojha et al. reported a high prevalence (47%) of respiratory tract infections caused by 72 bacterial pathogens among PLWH(5) and, factors associated with these infections include low 73 CD4 counts (<200 cells/ $\mu$ l) and detectable viral loads (5, 6).

74 HIV infection causes a progressive depletion of CD4 T cells as well as an impairment of cellular 75 and humoral immunity through a dysfunction of the T and B cells respectively (7). A dysfunction 76 of T cells leads to abnormal cellular responses while a dysfunction of B cells leads to a lack of 77 antibody responses to infections. The resultant immune dysfunction, deregulation and depletion 78 of CD4 lymphocytes causes an increased susceptibility to infections and the subsequent risk of 79 other complications like resistant pathogens (8, 9). HIV infection causes an alteration in lung host 80 defences for example, it affects mucociliary function which may contribute to an increase RTIs 81 among PLWH (9). PLWH are at increased risk of hospital acquired infections due to their frequent 82 contact with health care system through frequent clinic visits and admissions (10). The frequent 83 infections and admissions among PLWH, pill burden leading to unfinished doses and 84 inappropriate use of drugs through self-medication are some of the factors that have led to the 85 development of antimicrobial resistance among this population (11).

Antimicrobial resistance is an emerging global problem of public health importance (4). Previous 86 87 studies have reported a much higher prevalence of drug resistant bacteria among PLWH (79%) 88 compared to their HIV negative counterparts (30%) (10, 12). Prophylactic cotrimoxazole given to 89 PLWH over prolonged periods of time to prevent opportunistic infections has been reported to 90 give rise to antibiotic resistance (13). Resistant microbes are more difficult to manage since they 91 require alternative medications and or higher doses of drugs, both of which are more expensive, 92 not readily available in SSA and or toxic to the patient (13). Additionally, laboratory capacity for 93 identifying AMR is still limited in many parts of SSA; data are therefore still limited on 94 antimicrobial susceptibility patterns among PLWH in SSA (10). (10). It is important to understand 95 the common disease-causing pathogens among PLWH and current antibiotic susceptibility 96 patterns for better management. We studied the susceptibility pattern of microorganisms 97 isolated from respiratory samples taken from PLWH in central Uganda.

# 98 Methods

99 Study design, setting: We conducted a retrospective analysis of data collected during the 100 COSTOP trial (Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults in 101 Uganda: a randomised controlled trial, ISRCTN44723643) conducted between January 2011 and 102 March 2013 in two HIV care clinics in Masaka and Entebbe in central Uganda. (14, 15). 103 The COSTOP trial enrolled HIV positive adults (≥18 years) who had been on ART and 104 cotrimoxazole prophylaxis for at least six months, clinically asymptomatic and had CD4 cell

105 counts of >250 cells/mm<sup>3</sup> prior to enrolment. Individuals who had an acute illness, grade three

106 or four anaemia, neutropenia or thrombocytopenia, known hypersensitivity to cotrimoxazole,

107 and pregnant women were excluded.

#### **108 Participants and Eligibility**

The current analysis included COSTOP trial participants who presented to the clinic with a productive cough and provided sputum at any time during the trial. Participants were asked to collect sputum in a dry, leak proof, sterile container after rinsing their mouth with water. Samples were immediately transported to the laboratory for microscopy, culture, and sensitivity.

113 Laboratory: Samples were examined microscopically using Gram, Ziehl-Neelsen stains and 114 cultured on suitable bacteriological media (Blood, Chocolate, MacConkey agar and Subouroid 115 agar). Samples were incubated at 37<sup>o</sup>c for 24hrs, the pathogens that grew from incubated 116 samples were identified microscopically and biochemically using analytical profile index (API) and 117 by sensitivity testing. Antimicrobial sensitivity testing was done on isolated pathogens, by disc 118 diffusion technique(16). The diameter of the zone of inhibition was measured and compared to 119 that of European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards(17) to 120 determine resistance or sensitivity of a pathogen to the antimicrobial.

### 121 Study variables

The dependent variable was bacterial culture positivity of sputum collected during the study. The independent variables were gender, age (years) categorized under age groups <35years, 35-55 years and >55 years, recent and initial CD4 counts categorized into <200, 200-300 and >300 cells/ul, study arm in the COSTOP trial (cotrimoxazole arm, placebo arm), highest education level attained categorized into none, primary and secondary school, marital status categorized into married, divorced and single, monthly income (\$) categorized into those earning <30 and >/=30,

128 ART regimen categorized into First line and second line, duration on ART (years) and period since
129 HIV diagnosis (years).

130 Statistical analysis: The data collected were managed in MS Access, 2003 (Microsoft 131 Corporation, Redmond, WA) and data analyses were performed using Stata 14 (Stata Corp, 132 College Station, Texas 77845 USA) [11]. Continuous variables were presented as means with 133 standard deviation (SD) and categorical variables as frequencies and percentages. The proportion 134 of bacterial culture positivity overall, and by different participant characteristics were 135 determined as number culture positive divided by the total sample, expressed as a percentage. 136 A bar graph was used to display the frequency of bacterial isolates, and frequency and 137 percentages used to summarise antibacterial susceptibility of bacteria isolated in sputum. To 138 determine factors associated with bacterial culture positivity, we fitted both univariable and 139 multivariable logistic regression models. At univariable analysis, all factors in logit models with 140 likelihood ratio test p-value <0.2, were selected for multivariable logit model. Factors were 141 retained in the multivariable logit model if their inclusion did not make the model fit significantly 142 worse at p<0.05 on likelihood ratio test. We present the results as adjusted odds ratios (AOR) 143 with corresponding 95% confidence intervals (CI)

# 144 **Results**

### 145 **Participants' characteristics**

We included 687 participants in the analysis with mean age was 41.3 years (SD ±8.23) and 76.4%
were female. Overall, 51.1% of participants received cotrimoxazole, 70.2% earned less than \$30
monthly and 60.3% had primary level education. We observed that the mean period since HIV

149 diagnosis was 5.49 years (SD ±4.50) and the mean period on ART was 3.79 years (SD ±1.86) with

150 97.9% of participants on a first line ART regimen. Regarding CD4 counts, 89.7% had a recent CD4

151 of >300cell/μl however, 68.4% had a nadir CD4 count of <200cell/μl (Table 1).

152Table 1: Factors associated with b	pacterial growth	in sputum c	ultures amo	ong ART-experience	d HIV-
153positive individuals in Uganda (N=	687)				

Characteristic	N =687 n(%)	Culture positive (%)	OR (95% CI)	P-value	AOR (95% CI)	P-value
Sex						
Female	525 (76.4)	113 (21.5)	1		1	
Male	162 (23.6)	43 (26.5)	1.32 (0.88-1.98)	0.183	1.37 (0.89-2.11)	0.156
Age (years)						
<35	161 (23.4)	40 (24.8)	1			
35-55	482 (70.2)	110 (22.8)	0.89 (0.59-1.36)	0.599	0.91 (0.59-1.41)	0.666
>55	44 (6.4)	6 (13.6)	0.48 (0.19-1.21)	0.120	0.43 (0.17-1.13)	0.086
Receiving cotrimoxazole						
cotrimoxazole	351 (51.1)	71 (20.2)	1			
placebo	336 (48.9)	85 (25.3)	1.34 (0.93-1.91)	0.113	1.37 (0.94-1.98)	0.098
Education level						
None	101 (14.7)	26 (25.7)	1			
Primary	414 (60.3)	91 (22.0)	0.81 (0.49–1.34)	0.419		
Secondary	172 (25.0)	39 (22.7)	0.85 (0.48-1.50)	0.566		
Marital status						
Married	284 (41.3)	62 (21.8)	1			
Divorced	377 (54.9)	88 (23.3)	1.09 (0.75-1.58)	0.646		
Single	26 (3.8)	06 (23.1)	1.07 (0.41-2.79)	0.883		
Monthly income (\$)						
<30	448 (70.2)	109 (24.3)	1			
>/=30	190 (29.8)	38 (20.0)	0.78 (0.51-1.18)	0.236	0.63 (0.40-0.99)	0.049
Recent CD4*						
<200	11 (1.6)	1 (9.1)	1			
200-300	58 (8.4)	18 (31.0)	4.50 (0.53-37.85)	0.166	5.09 (0.58-44.60)	0.141
>300	616 (89.7)	137 (22.2)	2.86 (0.36-22.54)	0.318	2.86 (0.35-23.44)	0.326
Nadir CD4*						
<200	470 (68.4)	105 (22.3)	1			
200-300	123 (17.9)	30 (24.4)	1.12 (0.70-1.79)	0.629		
>300	18 (2.6)	4 (22.2)	0.99 (0.32-3.08)	0.991		
ART regimen*						
First line	662 (97.9)	151 (22.8)	1			
Second line	14 (2.1)	1 (7.1)	0.26 (0.03-201)	0.196	0.24 (0.03-1.94)	0.180

Duration on ART, (mean (SD)) yrs	3.79 (1.86)	3.75 (1.84)	0.98 (0.89-1.08)	0.726		
Years since HIV						
diagnosis, (mean (SD))	5.49 (4.50)	6.20 (6.83)	1.04 (1.00-1.09)	0.053	1.06 (1.01-1.11)	0.025
vrs						

154 ART = antiretroviral therapy; HIV = Human Immunodeficiency Virus

155

## 156 Bacterial culture positivity and prevalence of isolated microorganisms

157 A total of 201 (29.3%) samples had bacterial growth, with 9 samples growing more than one

158 bacterial organism. Isolated bacteria included Moraxella species (55, 27.4%), Streptococcus

159 pneumoniae (51, 25.4%), Haemophilus influenza (45, 22.4%), Mycobacterium species (11, 4.5%),

160 Pseudomonas species (8, 4.0%), Staphylococcus aureus (8, 4.0%), Escherichia coli (2, 1.0%),

161 *Klebsiella species* (2, 1.0%) and other bacteria (19, 10.4%) (Figure 1).

## 162 Factors associated with bacterial culture positivity

163 The factors found to be independently associated with having a bacterial culture positive sample

164 where; monthly income > \$30 (aOR= 0.63, 95%CI 0.40-0.99) compared to those earning below

165 \$30 and longer duration of years since HIV diagnosis [aOR= 1.06, 95% CI 1.01-1.11]. Participants

166 who received placebo were more likely to have a positive sputum culture than those who

167 received cotrimoxazole however this was not found to have statistical significance (aOR= 1.37,

168 95% CI 0.94-1.98) (Table 1).

### 169 Antibiotic sensitivity of isolated microorganisms

The sensitivity of bacterial isolates is shown in Table 2. Most isolates were highly sensitive to Amoxicillin + Clavulanic acid and ceftriaxone with *Moraxella sp. and, Streptococcus pneumoniae* having 100% sensitivity to both. *Pseudomonas* had 100% sensitivity to gentamycin while H. *influenza* showed 100% sensitivity to ceftriaxone and 88.6% sensitivity to Amoxicillin + Clavulanic acid. Other bacteria showed the highest sensitivity to ceftriaxone and gentamycin (85.7%). 175 All isolates had very low sensitivity to cotrimoxazole (<16.7%). Moraxella sp, H. influenza and Pseudomonas showed zero sensitivity to

176 cotrimoxazole. Moraxella sp (28.8%), H. influenza (31.6%), S. aureus (42.9%) and other bacteria (42.9%) also had low sensitivity

177 towards erythromycin. H. *influenza* (50.0%) and other bacteria (69.2%) had relatively low sensitivity towards ciprofloxacin.

178 **Table 2:** Antibacterial susceptibility rates of bacterial isolated from sputum of PLWH.

179

	Moraxella species		Streptococcus pneumoniae			Haemophilus influenza		Pseudomonas species		Staphylococcus aureus			Others					
	N=55		N=51		N=45		N=8		N=8			N=34						
	Т	S	<b>S%</b>	Т	S	S%	т	S	<b>S%</b>	Т	S	S%	т	S	<b>S%</b>	т	S	S%
Cotrimoxazole	43	0	0.0	39	1	2.6	37	0	0.0	3	0	0.0	6	1	16.7	21	2	9.5
Erythromycin	42	12	28.6	38	30	78.9	38	12	31.6	0	0	n/a	7	3	42.9	7	3	42.9
Amoxyl+clavulanic acid	42	42	100.0	4	4	100.0	35	31	88.6	0	0	n/a	6	6	100.0	7	6	85.7
ciprofloxacin	0	n/a	n/a	0	n/a	n/a	2	1	50.0	5	4	80.0	0	n/a	n/a	13	9	69.2
Ceftriaxone	2	2	100.0	35	35	100.0	1	1	100.0	2	1	50.0	0	n/a	n/a	13	10	76.9
Gentamycin	0	n/a	n/a	0	n/a	n/a	0	0	n/a	5	5	100.0	0	n/a	n/a	14	12	85.7

180 NOTE: Amoxyl + clavulanic acid = Amoxicillin + Clavulanic acid, T = number tested, S = sensitivity

# 182 **Discussion**

183 We cultured sputum from ART experienced PLWH with a productive cough and approximately 184 30% of the sputum samples had bacterial growth. This is similar to what was reported by 185 Akingbade OA et al who found a prevalence of 24.2% positive cultures from sputum collected 186 from participants with lower RTIs (18), but lower than approximately 44% prevalence reported 187 by Adhanom et al (19). Adhanom et al included both ART experienced and ART naïve participants 188 that were suspected of pneumonia, which more a severe disease than the presentation of cough 189 that was considered in our study. Our participants were all ART experienced, indicating they 190 might have had a better immunity than those included in Adhanom et al study. Additionally, 191 Adhanoum et al's study was conducted in three years after the COSTOP study, during which 192 period there might have been an increase in antimicrobial resistance, leading to reduced 193 response by the bacteria to antibiotics hence increased bacterial growth on culture.

194 We found a high prevalence of *Moraxella species* (28%) in our sputum samples. *Moraxella species* 195 is usually normal flora of the respiratory tract, however, previous studies have reported 196 Moraxella as a pathogen of the lower respiratory tract in immunosuppressed patients (20). 197 Abdullah et al reported a relatively high prevalence of *Moraxella* in patients with lower RTIs 198 among the elderly and immunosuppressed (20). Our finding of high proportion of participants 199 with *Moraxella species* may indicate a less than complete immune recovery in these patients. 200 The Moraxella species isolated in our study was sensitive to amoxicillin+ clavulanic acid and 201 ceftriaxone and had very low sensitivity to erythromycin and cotrimoxazole, which is similar to 202 what Abdullah et al reported (20). The very low sensitivity of all the bacterial isolates to

203 cotrimoxazole is not surprising since our study participants were either on active cotrimoxazole
 204 prophylaxis, or had previously used cotrimoxazole prophylaxis.

HIV infection leads to a low CD4 count and a defective immune system which renders people infected with the HIV virus susceptible to microbial infections leading to a greater use of antibiotics among people living with HIV. The increased use of antibiotics may explain the observed low sensitivity of isolated bacteria to cotrimoxazole (21), and erythromycin (20) among PLWH in this study and other studies.

210 Participants that received placebo were more likely to have a positive sputum culture compared 211 to those receiving cotrimoxazole, however this was not statistically significant. This implies that 212 use of Cotrimoxazole did not provide protection against respiratory infections in this study 213 population. This could be due to the fact that the study participants were ART experienced, had 214 improved and stabilised immunity, and thus were no longer susceptible to infections associated 215 with compromised immunity. Although the study was not powered to answer the question on 216 the effect of cotrimoxazole on respiratory bacterial infections, this finding supports the 2020 217 Uganda HIV prevention and treatment guidelines that recommends use of prophylactic 218 cotrimoxazole only in adults with advanced HIV disease, those newly diagnosed with HIV, 219 children below 18 years, pregnant and breastfeeding women (22). An association of long term use 220 of cotrimoxazole among PLWH with an increase in resistance to cotrimoxazole has been reported 221 in previous studies (23, 24) therefore, reduced use of cotrimoxazole in this population may 222 reduce resistance of microbes to it.

The participants in the study were generally low earners as majority of them were earning less than \$30 a month. Participants who earned more than \$30 were less likely to have positive

bacterial cultures compared to those who earned less than \$30. This is similar to evidence that suggests that those with lower socio-economic status are more vulnerable, have higher burden

of disease and thus more prone to frequent respiratory infections (25).

228 Participants who had a longer duration since HIV diagnosis were more likely to have a positive

229 bacterial culture. This finding requires further investigation since there is no clear biological

230 explanation between duration of HIV infection and risk of bacterial infections.

### 231 Strengths and Limitations

This study among ART experienced participants has applicable results as majority of PLWH are on ART following the test and treat policy. Previous studies have mainly reported antimicrobial sensitivity among ART naïve patients. The study was however, a secondary data analysis and this limited the number of antimicrobial drugs that could have been tested for bacterial sensitivity. We could also not explore other factors for example viral load, that could be associated with a positive sputum culture.

# 238 **Conclusion**

High prevalence of bacterial isolates with most being susceptible to Amoxicillin + Clavulanic acid and ceftriaxone. However, majority of organisms showed very low sensitivity to cotrimoxazole and erythromycin that are cheaper and readily available. As antibiotic choices are becoming limited due to low sensitivity of microbes to these drugs, there is an urgent need to invest in the prevention and control of increasing antibiotic resistance.

244 Acknowledgements

- 245 We would like to acknowledge the contributions of the COSTOP trial team and the contribution
- 246 of the study participants
- 247 Competing interests
- 248 The authors declare no competing interests.

### 249 Ethical approval statement

- 250 All participants enrolled into the main COSTOP trial gave written informed consent prior to any
- 251 study procedures. The COSTOP study received approval from Uganda Virus Research Institute
- 252 Ethics committee, National Drug Authority and Uganda National Council for Science and
- 253 Technology.

## **Author Contributions:**

- LG conceived and designed the study, participated in data collection, analysis and interpretation,
- AA contributed to data analysis. All authors read, revised the original manuscript and approved
- the final version of manuscript.
- 258

### 259 **References**

260 1. UNAIDS. Global HIV & AIDS statistics - Fact sheet 2021 [Available from:

261 https://www.unaids.org/en/resources/fact-

262 <u>sheet#:~:text=GLOBAL%20HIV%20STATISTICS,AIDS%2Drelated%20illnesses%20in%202020</u>.

263 2. Barankanira E, Molinari N, Niyongabo T, Laurent C. Spatial analysis of HIV infection and

associated individual characteristics in Burundi: indications for effective prevention. BMC Public Health.
 2016;16(1):118.

- Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes of hospital admission
   among people living with HIV worldwide: a systematic review and meta-analysis. The lancet HIV.
   2015;2(10):e438-44.
- 4. Gauchan P, Lekhak B, Sherchand JB. The prevalence of lower respiratory tract infection in adults visiting Tribhuvan University Teaching Hospital. Journal of Institute of Medicine Nepal. 2007;28(2):10-4.
- 5. Ojha CR, Rijal N, Khagendra KC, Palpasa K, Kansakar P, Gupta BP, et al. Lower respiratory tract
- infections among HIV positive and control group in Nepal. VirusDisease. 2015;26(1):77-81.

Lamas CC, Coelho LE, Grinsztejn BJ, Veloso VG. Community-acquired lower respiratory tract
 infections in HIV-infected patients on antiretroviral therapy: predictors in a contemporary cohort study.
 Infection. 2017;45(6):801-9.

276 7. Cairns G. HIV damages B-cells as well as T-cells: new treatment targets identified NAM-

aidsmap2011 [Available from: <a href="https://www.aidsmap.com/news/jun-2011/hiv-damages-b-cells-well-t-">https://www.aidsmap.com/news/jun-2011/hiv-damages-b-cells-well-t-</a>
 cells-new-treatment-targets-identified

278 <u>cells-new-treatment-targets-identified</u>.

- 2798.Okoye AA, Picker LJ. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological280failure. Immunol Rev. 2013;254(1):54-64.
- 281 9. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, et al. HIV infection
   and risk for incident pulmonary diseases in the combination antiretroviral therapy era. American journal
   of respiratory and critical care medicine. 2011;183(3):388-95.
- 284 10. Olaru ID, Tacconelli E, Yeung S, Ferrand RA, Stabler RA, Hopkins H, et al. The association
- between antimicrobial resistance and HIV infection: a systematic review and meta-analysis. Clinical
   microbiology and infection : the official publication of the European Society of Clinical Microbiology and
   Infectious Diseases. 2021;27(6):846-53.
- 11. Rameshkumar MR, NarasingamArunagirinathan, editors. Drug-Resistant Bacterial Infections in
   HIV Patients2018.
- Marbou WJT, Kuete V. Bacterial resistance and immunological profiles in HIV-infected and non infected patients at Mbouda AD LUCEM Hospital in Cameroon. Journal of Infection and Public Health.
   2017;10(3):269-76.
- 29313.Arunagirinathan MRRaN. Drug-Resistant Bacterial Infections in HIV Patients, Advances in HIV294and AIDS Control. IntechOpen. 2018.
- Anywaine Z, Abaasa A, Levin J, Kasirye R, Kamali A, Grosskurth H, et al. Safety of discontinuing
  cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP
  trial): Design. Contemporary clinical trials. 2015;43:100-4.
- Anywaine Z, Levin J, Kasirye R, Lutaakome JK, Abaasa A, Nunn A, et al. Discontinuing
  cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in
  Uganda (COSTOP): A randomised placebo controlled trial. PloS one. 2018;13(12):e0206907.
- 301 16. Novick Jr WJ. Development of in vitro susceptibility testing criteria and quality control
   302 parameters. Elsevier; 1989. p. 60-2.
- 30317.Leclercq R, Cantón R, Brown DFJ, Giske CG, Heisig P, MacGowan AP, et al. EUCAST expert rules in304antimicrobial susceptibility testing. Clinical Microbiology and Infection. 2013;19(2):141-60.
- A A, Ogiogwa J, Okerentugba P, Innocent-Adiele C, Onoh C, Nwanze J, et al. Prevalence of
   Antibiotic Susceptibility Pattern of bacterial Agents Involve In lower Respiratory Tract Infection in
   Abeokuta ,Ogun State ,Nigeria. Report and Opinion. 2012.
- 30819.Adhanom G, Gebreegziabiher D, Weldu Y, Gebreyesus Wasihun A, Araya T, Legese H, et al.309Species, Risk Factors, and Antimicrobial Susceptibility Profiles of Bacterial Isolates from HIV-Infected
- Patients Suspected to Have Pneumonia in Mekelle Zone, Tigray, Northern Ethiopia. BioMed Research
- 311 International. 2019;2019:8768439.
- Abdullah FE, Ahuja KR, Kumar H. Prevalence and emerging resistance of Moraxella catarrhalis in
   lower respiratory tract infections in Karachi. JPMA The Journal of the Pakistan Medical Association.
   2013;63(11):1342-4.
- 315 21. Oguche JI-o, Bolaji RO, Onaolapo JA, Abah SE, Kwaghe VG, Akor SE, et al. BACTERIAL INFECTION
- 316 AND ANTIBIOTIC RESISTANCE IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS PRESENTING
- 317 LOWER RESPIRATORY TRACT INFECTION IN NIGERIA. medRxiv. 2021:2021.09.05.21263138.
- 318 22. Health Mo. CONSOLIDATED GUIDELINES FOR THE PREVENTION AND TREATMENT OF HIV AND
- 319 AIDS IN UGANDA 2020 [Available from:

- 320 <u>https://differentiatedservicedelivery.org/Portals/0/adam/Content/HvpzRP5yUUSdpCe2m0KMdQ/File/U</u>
   321 ganda Consolidated%20HIV%20and%20AIDS%20Guidelines%202020%20June%2030th.pdf.
- 322 23. Martin JN, Rose DA, Hadley WK, Perdreau-Remington F, Lam PK, Gerberding JL. Emergence of
- trimethoprim-sulfamethoxazole resistance in the AIDS era. The Journal of infectious diseases.

324 1999;180(6):1809-18.

- 325 24. Zachariah R, Harries AD, Spielmann MP, Arendt V, Nchingula D, Mwenda R, et al. Changes in
- 326 Escherichia coli resistance to co-trimoxazole in tuberculosis patients and in relation to co-trimoxazole
- prophylaxis in Thyolo, Malawi. Malawi medical journal : the journal of Medical Association of Malawi.
   2002;14(2):10-2.
- 329 25. Kiwanuka SN, Ekirapa EK, Peterson S, Okui O, Rahman MH, Peters D, et al. Access to and
- 330 utilisation of health services for the poor in Uganda: a systematic review of available evidence.
- 331 Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008;102(11):1067-74.

# **Frequency of bacterial isolates**



**Fig. 1** Frequency of bacterial isolates. Figure